anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Tacrolimus (Prograf) belongs to a class of medications known as the calcineurin inhibitors. It is a maintenance drug that is used to prevent rejection in kidney, liver, and heart transplant recipients. Calcineurin inhibitors display high pharmacokinetic (the body's effects on a drug) variability and necessitate use of blood tests to ensure that adequate drug levels are present to maintain effectiveness and safety. The amount of oral tacrolimus that is absorbed varies in all patient populations studied. Tacrolimus is metabolized or broken down for elimination by the liver and small intestine via cytochrome P450 (CYP)3A4, CYP 3A5, and p-glycoprotein enzyme systems. Enzyme activity is affected by several single nucleotide polymorphisms (SNPs) in an individuals genetic make-up and differences in expression may contribute to variations in tacrolimus pharmacokinetics. There are number of drug-drug interactions where concomitantly administered medications can increase or decrease this break down of tacrolimus. Early after transplant or at times when tacrolimus cannot be taken by mouth, alternative routes of administration are sought. Although an intravenous (through the vein) product is available, it can be toxic to the kidneys and has been associated with allergic reactions. Studies in lung transplant recipients have utilized sublingual (under the tongue) tacrolimus administration with successful outcomes. Drug delivery via the oral mucosa is an alternative method of systemic drug administration which offers an alternative when oral administration is impractical (gastrointestinal dysmotility, reduced drug absorption, intestinal failure, difficulty in swallowing, or in those with nausea or vomiting). Administration of tacrolimus by the sublingual route allows for direct entry into the systemic circulation and bypasses problems associated with drug absorption and breakdown that take place in the small intestine. In order to learn more about the possible role of sublingual tacrolimus among transplant recipients we will administer tacrolimus sublingually. In addition, we will evaluate differences in expression and bioactivity of SNP polymorphisms and their effects in tacrolimus pharmacokinetics. Patients awaiting kidney transplantation who are listed on the kidney transplant waiting list or those with upcoming living donor transplants at our center will be administered five doses of sublingual tacrolimus followed by five doses of oral tacrolimus. We will evaluate and then compare the pharmacokinetic characteristics of sublingual and oral tacrolimus administration among the study participants. The purpose of this study is to assess the pharmacokinetic and pharmacodynamic parameters of tacrolimus after sublingual and oral administration. A secondary objective is to assess the drug-drug interaction between concomitant therapy with clotrimazole.
Participants with pediatric Crohn's disease (CD) who were treated with Infliximab (IFX) and signed the Informed Consent Form (ICF) for the study will be enrolled case by case. Each participants will be followed up for at least 30 weeks. After 30 weeks, participants continuing IFX treatment will be followed up, with a maximum follow-up period of 102 weeks. The primary data source will be participants medical records for all data entered into the CRF.
PURPOSE: To determine the recurrence and reactivation rates after teprotumumab therapy for active thyroid eye disease.
DESIGN: Retrospective consecutive case series.
METHODS: This was a study of all patients followed for active thyroid eye disease at the Cole Eye Institute, Cleveland Clinic, treated with teprotumumab between May 2020 and May 2021. Patients with less than 6 months follow-up after completion of infusions were excluded. The primary outcome measure was reactivation, defined as a regression in proptosis (increase of ≥2 mm in either eye and to within ≤2 mm of pre-treatment level and Clinical Activity Score [CAS] worsening of 2 points or greater). Secondary outcome was diplopia response.
RESULTS: A total of 21 patients were included in the study. The average long-term improvement in proptosis in the eye with more proptosis after teprotumumab was 1.57mm (range, -3 to 4 mm). Of the 17 initial responders, there were 8 reactivations (47%) and 2 isolated proptosis regressions (12%); Overall, 7 of 21 patients (33%) responded throughout the study period. Average time to regression was 12.25 months (range, 2-22.5 months). There was no statistically significant change in diplopia at final visit in any subgroup (P = 0.68 to >.99).
CONCLUSIONS: At most, 33% of patients demonstrate continued response 2 years after teprotumumab treatment. The proptosis and CAS regression occurs in the setting of disease reactivation in 80% of regressions. Teprotumumab treatment appears to offer minimal long-term improvement in diplopia.
PURPOSE:To obtain an adhesive for dentistry consisting of a composition containing a three functional isocyanate compound or composition obtained by blending the three functional isocyanate compound with an inert diluent and composition containing a radical polymerizable unsaturated monomer, radical polymerization initiator and polymerizable phosphoric acid ester compound. CONSTITUTION:The aimed adhesive for dentistry consisting of (A) three functional isocyanate compound (e.g. reaction product of 1mol trimethylolpropane and 3 mol diisocyanate compound) or a composition obtained by blending the three functional isocyanate compound with an inert diluent (e.g. acetone or toluene) and (B) composition containing a radical polymerizable unsaturated monomer (e.g. methyl methacrylate or polyethylene glycol diacrylate), radical polymerization initiator and polymerizable phosphoric acid ester (e.g. methacryloyloxyethylene phosphate). The adhesive has excellent advantages obviating troublesome pretreatment by etching agent and giving no stimulation to dental pulp.
All patients will receive fludarabine, busulfan and cyclophosphamide as the conditioning regimen prior to an allo SCT. Patients will then receive 2 doses of cyclophosphamide post-transplant and utilize sirolimus and mycophenolate mofetil (in mismatched transplants) as GVHD prophylaxis.
Participants will receive JNJ-42847922, 20 milligram (mg) on Day 1 and Day 6. Participants will receive rabeprazole 20 mg once daily from Day 2 to Day 6.
The invention discloses a cleaning wet wipe containing pharmaceutical grade witch hazel extract. The cleaning wet wipe comprises a matrix material and medicinal soup impregnating into the matrix material. The medicinal soup is prepared from the following raw materials by weight: 30 to 60% of pharmaceutical grade witch hazel extract, 0.01 to 0.1% of plant essence, 0.1 to 0.5% of antiseptic, 0.01 to 0.5% of an auxiliary agent, 0.01 to 0.1% of a stabilizing agent and a proper amount of a pH value conditioning agent, with the balance being pure water. The pH value of the medicinal soup is in a range of 4.5 to 6.5. The cleaning wet wipe provided by the invention overcomes defects of the prior art and has astringing, anti-inflammatory, antioxidative, antibacterial, soothing, skin-nourishing and vasoconstriction-promoting effects and the like. Through combination of a spunlaced non-woven fabric with the medicinal soup containing the pharmaceutical grade witch hazel extract, the cleaning wet wipe containing the pharmaceutical grade witch hazel extract is convenient to use, does not need other auxiliary articles, is a disposable product and causes no cross contamination.
INTRODUCTION: Soft-tissue sarcoma (STS) is a rare cancer of the connective tissues requiring invasive treatment. Due to the complexity of treatment, STS patients experience more functional impairment and disability than other oncologic populations. Given that extant literature is unclear and exclusively focused on physical function, the objectives of this study were to use the Wilson-Cleary Model of HRQL to evaluate the extent to which biological function (tumor site, depth and size), symptoms (fatigue, pain, anxiety/depression), and functional status are associated with the health perceptions of soft-tissue sarcoma patients 12 months post-op.
METHODS: Data were drawn from an inception cohort study at the McGill University Health Centre. Inclusion criteria included 18 years of age and a biopsy-confirmed diagnosis of STS. Those with evidence of metastasis at diagnosis or less than 12 months of follow-up were excluded. Statistical analyses included T-tests, Pearson correlations, and multiple linear regression.
RESULTS: 331 patients were included (185 males, 146 females) with mean (SD) ages of 56 (17). Significantly more females reported pain and anxiety/depression. Self-reported function was significantly higher in males. Overall, the regression model explained 53 % of the variance in health perceptions in males, and 48 % in females. Only self-reported function was significantly associated with health perceptions in males (B = 0.34) and females (B = 0.48). Further, compared to females without pain, females with pain perceived their health as significantly worse.
CONCLUSION: Evaluating health perceptions with a multidimensional lens revealed new information about the STS patient experience. Findings suggest that key targets include routine psychosocial distress monitoring and addressing rectifiable disability-related barriers promptly.
Provided is a single-stranded oligonucleotide capable of controlling a gene of interest at high efficiency and being produced easily. A single-stranded oligonucleotide represented by formula (I), where X is represented by Xa-Xb, Xa links to Y, and Xb and Y hybridize. Xa comprises 1-40 nucleotides and includes at least one modified nucleotide. Xb comprises 4-40 nucleotides and includes at least one modified nucleotide. Y comprises 4-40 nucleotides and includes at least one ribonucleotide. Xz and Yz comprise 5-40 nucleotides and include at least one modified nucleotide. Nucleotide sequences X, Xz, and Yz have an antisense sequence that can hybridize with an RNA of interest. Lx and Ly comprise 0-20 nucleotides.
METHODS: The study intends to include patients undergoing planned major surgery at the surgery department at Karolinska University Hospital Huddinge. Before surgery, patients will be asked and written informed consent for participation will be obtained. Within the framework of the study, measurement with the newer measurement method on the nose is planned to be done at the same time as standard measurement on the finger is performed. The research study and oxygen saturation measurement with the nasal clamp starts when the patient enters the operating room and continues until he or she leaving the post-operative ward the day after surgery, or at the latest 24 hours after the start of the operation. Apart from the use of two body oxygenation monitors, there is no impact on the treatment and care are not affected at all. Decisions and actions based on possible changes in oxygenation will be based primarily on the traditional measurement point in the finger. After completion of the study, all anesthesia nurses and all nurses from the surgical and postoperative department in Huddinge who have worked with the Alar SpO2 (saturation) sensor during the study will be invited to participate in a semi-structured interview. All nurses who express interest in participating will receive an information sheet and consent will be signed personally with the signed personally with the interviewer before the interview starts. The investigators will collect data on staff opinions regarding the use of the Alar SpO2 sensor (such as: the differences between the Alar SpO2 sensor and the finger SpO2 sensor, the advantages and disadvantages of the Alar SpO2 sensor, advantages of using dual oximetry, and potential expansion of the work with the Alar SpO2 sensor).
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: application of alpha-1-antitrypsin (AAT) for preparing a drug for treating chronic fatigue syndrome (CFS) is offered. It is shown: AAT inhibited intracellular elastase activity of mononuclear cells of peripheral blood of the CFS patients, prevented degradation RNAase L 83 kDa with formation of the overactive RNAase L 37 kDa form. After treating with the preparation AAT, elastase activity in the specified blood cells decreased from approximately 1459 U/mg to 134 U/mg; the patient showed obvious clinical improvements, decreased cognitive disorders cognitive infringements, has went back to work. Particularly, the invention refers to the application of plasma or other therapeutic forms containing alpha-1-antitrypsin sufficient for produce a dosage of alpha-1-antitrypsin equal to 6 mg or more per one kg of body weight with frequency 1 to 31 days. ^ EFFECT: higher clinical effectiveness. ^ 4 cl
BACKGROUND: Patients with pancreatic ductal adenocarcinoma present early postoperative systemic metastases, despite complete oncological resection. The aim of this study was to assess two pancreatoduodenectomy approaches with regard to intraoperative circulating tumour cells and cluster mobilization and their potential association with the development of distant metastasis.
METHODS: Patients with periampullary tumours who underwent open pancreatoduodenectomy were randomly allocated to either the no-touch approach or the superior mesenteric artery approach. A total of four intraoperative portal vein samples (at the beginning of the intervention, after portal vein disconnection from the tumour, after tumour resection, and before abdominal closure) were collected to measure circulating tumour cells and cluster numbers. Primary outcomes were the intraoperative number of circulating tumour cells and cluster mobilization. Further, their potential impact on 3-year distant metastasis disease-free survival and overall survival was assessed.
RESULTS: A total of 101 patients with periampullary tumours were randomized (51 in the superior mesenteric artery group and 50 in the no-touch group) and 63 patients with pancreatic ductal adenocarcinoma (34 in the superior mesenteric artery group and 29 in the no-touch group) were analysed. Circulating tumour cells and cluster mobilization were similar in both the no-touch group and the superior mesenteric artery group at all time points. There were no significant differences between surgical groups with regard to the median metastasis disease-free survival (12.4 (interquartile range 6.1-not reached) months in the superior mesenteric artery group and 18.1 (interquartile range 12.1-not reached) months in the no-touch group; P = 0.730). Patients with intraoperative cluster mobilization from the beginning to the end of surgery developed significantly more distant metastases within the first year after surgery (P = 0.023). Two intraoperative factors (the superior mesenteric artery approach (P = 0.025) and vein resection (P < 0.001)) were predictive factors for cluster mobilization.
CONCLUSION: Patients undergoing pancreatoduodenectomy using either the no-touch approach or the superior mesenteric artery approach had similar circulating tumour cells and cluster mobilization and similar overall survival and metastasis disease-free survival. A high intraoperative cluster dissemination during pancreatoduodenectomy was a predictive factor for early metastases in patients with pancreatic ductal adenocarcinoma.
REGISTRATION NUMBER: NCT03340844 (http://www.clinicaltrials.gov)-CETUPANC trial.
FIELD: medicine. SUBSTANCE: method involves placing penis into laboratory flask where the pressure is lowered down to 0.3-0.6 atm. Then, one or several medical preparation solutions are supplied into the laboratory flask. Solution temperature is equal to 36-42 C, exposure time is 5-12 min. The procedure is repeated daily or each second day 5-10 times. EFFECT: improved clinical results also in cases of aged patients.
SB-509 contains the gene (DNA-a kind of biological "blueprint") for a protein. When a researcher injects SB-509 into your legs, the drug enters the muscle and nerve cells around the injection site and causes these cells to make a protein. This protein causes your cells to increase production of another protein called vascular endothelial growth factor (VEGF), which may improve the structure and function of nerves. In addition, there are changes in the levels of 28 additional proteins in your cells. These proteins function to promote the growth of cells, are structures in cells, help synthesize products, and affect immune cells, and some have unknown functions. This increase in your own VEGF proteins may protect and repair the damaged nerves caused by diabetic neuropathy.

The study doctor will test SB-509 (60 mg) and placebo. Everyone in this study will receive intramuscular (IM-directly into the muscle) injections into both legs. This will happen 3 times over about 4 months. Two out of every 3 participants will receive SB-509 and 1 out of every 3 will receive placebo. You will not know, and the study doctor will not know, whether you will receive SB-509 or whether you will receive placebo.
“Enhydrazone esters of formula (I): wherein R is methyl or ethyl group have been synthesized. The compounds of formula (I) are potent inhibitors of degranulation of both mast cells and eosinophils. These compounds also suppress cytokines generation by leukocytes. These biological activities are relevant to the prevention and/or treatment of asthma, allergies and inflammatory diseases. It is known to the art that inhibitors of mast cell degranulation such as cromolyn sodium and nedocromil sodium are used in the treatment of asthma and other allergic diseases. Inhibitors of cytokine generation, such as steroids, are also useful in the prevention and treatment of inflammatory diseases as well as asthma and allergies”.
Patients admitted for surgery because of peroneal tendon injury will be randomized to one of two postoperative immobilization protocols. In group A the patients will use a cast for 6 weeks after surgery. In group B, the patients will use a cast for 3 weeks followed by a Air Stirrup for 3 weeks. The patients in group B will start unloaded range of motion 3 weeks after surgery. Both groups are allowed to weight-bear directly after surgery. The patients will be evaluated before and several times after surgery. Patient-reported outcome measures (PROMs) will be used to evaluate changes in patient quality of life between the two interventions. A biomechanical evaluation of the ankle, knee and hip kinematics and kinetics during walking, running and walking will also be performed before and repeatedly after surgery.
INTRODUCTION: We performed a cross-sectional study using the Centers for Disease Control and Prevention's (CDC's) Wide-Ranging Online Data for Epidemiologic Research (WONDER) database to analyze the trends in cardiac implantable electronic device (CIED) infection-related mortality from 1999 to 2020.
METHODS: We analyzed the death certificate data from the CDC WONDER database from 1999 to 2020 for CIED infections in the US population aged ≥25 years using International Classification of Diseases, Tenth Revision (ICD-10) codes, listed as the underlying or contributing cause of death. Age-adjusted mortality rates (AAMR) and 95% confidence intervals (CIs) were computed per 1 million population by standardizing crude mortality rates to the 2000 US census population. To assess annual mortality trends, we employed the Joinpoint regression model, calculating the annual percent change (APC) in AAMR and corresponding 95% CIs.
RESULTS: Overall, there was an observed declining trend in AAMRs related to CIED infection-related mortality. Males accounted for 55% of the total deaths, with persistently higher AAMRs compared to females over the study duration. Both males and females had an overall decreasing trend in AAMRs throughout the study duration. On race/ethnicity stratified analysis, non-Hispanic (NH) Blacks exhibited the highest overall AAMR, followed by NH American Indians or Alaska Natives, NH Whites, Hispanic or Latinos, and NH Asian or Pacific Islanders. On a stratified analysis based on region, the South region had the highest overall AAMR, followed by the Midwest, West, and Northeast regions.
CONCLUSION: Our study demonstrates a significant decline in CIED infection-related mortality in patients over the last two decades. Notable gender, racial/ethnic, and regional differences exist in the rates of mortality related to CIED infections.
The HP group will be provided with the respective breakfast meals to consume, at home, between 6:00-8:00 am each day over the 4-mo intervention. The energy content of the breakfast meals will be standardized to 350 kcal. The HP breakfasts will be 34% protein (30 g protein), 40% CHO, and 26% fat.
These are breast implant devices and methods of use. The breast implants are made of a matrix of collagen material having a porous structure for supporting surrounding tissue of a breast. The implants are also configured to provide a framework for the in-growth of fibrous tissue into the matrix. The matrix can be resilient and/or self-expanding. The methods of use include the steps of forming a cavity having surrounding breast tissue and forming a resorbable implant made up of collagen that is sized to occupy the cavity. The implant is then implanted into the cavity, thereby supporting the surrounding tissue and allowing for in-growth of fibrous tissue into and replacing the resorbable material. The resorbable material may also be elastically compressible, such that the step of implanting includes the step of compressing the resorbable material. The implants may also contain a medicinal, therapeutic, or diagnostic substance.
<P>PROBLEM TO BE SOLVED: To provide an immune response-modulating composition and food containing the same useful for treating/preventing various immunological diseases including food allergy.  <P>SOLUTION: The immune response-modulating composition comprises at least one substance selected from the group consisting of protein having immunomodulating function such as albumen ovomucoid, the protein's split product having immunomodulating function and chemically modified product thereof having immunomodulating function and lactic acid bacteria selected from the microorganism group belonging to the genera Lactobacillus, Bifidobacterium and Enterococcus and enabling immunomodulating function to be improved via synergistic action with the above-mentioned chemical substance(s) through inducing Th1-type cytokine(e.g. IL-12, IFN-γ) and Th2-type cytokine(e.g. IL-6, IL-10). The food with the above composition as active ingredient is also provided.  <P>COPYRIGHT: (C)2007,JPO&INPIT
The invention discloses rose flower residue exfoliating massaging bathing cream and a preparing method thereof, and belongs to the field of daily use chemicals. The rose flower residue exfoliating massaging bathing cream is mainly composed of rose flower residue, highland barley powder, oat powder, roseleaves, rose essential oil, olive oil, mineral butter and non-ionic surface active agent. Most of current merchant exfoliating products aim at skin of face, and the products contain chemical substances, thus having large skin irritation, therefore, long-term use of the products can cause skin problems. The rose flower residue exfoliating massaging bathing cream is composed of pure natural plants, and the rose flower residue is adopted as a main component of the exfoliating massaging bathing cream and is made use of, thus wasting of resources is avoided. According to the rose flower residue exfoliating massaging bathing cream, irritation and side effects are not generated in the using process, and the cream can be used for a long time and is applicable to exfoliating of the whole body. The rose flower residue exfoliating massaging bathing cream can gently remove cutin accumulation caused by metabolism and drying and water shortage of human body, relieve stress of the skin, effectively repair dry skin, and make the skin moisten enduringly.